SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Oliver Gautschi

Oliver Gautschi

Luzerner Kantonsspital (LUKS), Lucerne

Prof. Oliver Gautschi is Chief Physician of Medical Oncology for the Luzerner Kantonsspital (LUKS) Group in Lucerne, Switzerland, and Titular Professor of Medical Oncology at the University of Bern. His work centers on thoracic oncology, including molecularly targeted therapy and immunotherapy for non-small cell lung cancer, and he was first author of the global RET registry study in RET-rearranged lung cancer and a lead investigator on the BRAF-mutant EURAF cohort and the IMMUNOTARGET registry. He serves as Vice-President of the Swiss Academy of Multidisciplinary Oncology (SAMO) and is a member of ESMO, the European Thoracic Oncology Platform, and the IASLC. He is a frequent speaker at major international lung cancer congresses.

Connect

Oliver Gautschi

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates